# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Arthur He reiterates Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and maintains $4 pric...
HC Wainwright & Co. analyst Arthur He reiterates Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and maintains $4 pric...
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large jo...
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA...